Under the Master Collaboration Agreement, Qiagen will develop and validate a real-time in vitro PCR test that can be used to detect IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates.
The companion diagnostic will run on the Qiagen Rotor-Gene Q MDx device, which is widely used by labs worldwide.
Qiagen's experienced regulatory teams will support clinical validation of the companion diagnostic and its approval in the US, the European Union and Japan.
AML is a hard-to-treat cancer of the blood and bone marrow. IDH1 mutations are present in about 6 to 10 % of cases1. One of the most common types of leukemia in adults, the disease often occurs in patients in their late 60s or older.
Qiagen is in precision medicine and a leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics.
These can detect genetic abnormalities to provide insights that guide clinical decision-making about treatments.
From polymerase chain reaction and digital PCR to next-generation sequencing, Qiagen offers an unmatched breadth of technologies, which means it can tailor products to partners' needs.
Qiagen has master collaboration agreements to develop and commercialize companion diagnostics with more than 30 global companies a deep pipeline that will advance so-called precision medicine, which tailors a patient's treatment to the genetic profile identified by companion diagnostics testing.
Qiagen currently has eleven PCR-based companion-diagnostics tests that have been approved by the US Food and Drug Administration.
Furthermore, the company announced collaborations with Neuron23 and Helix to develop companion diagnostics in disease areas outside oncology.
Qiagen N.V., a Netherlands-based holding company, is a global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life.
As of September 30, 2022, Qiagen employed more than 6,200 people in over 35 locations worldwide.
Carisma Therapeutics' CT-0525 IND application receives US FDA approval
Orexo's OX124 New Drug Application accepted for review by US Food and Drug Administration
GE HealthCare expands Critical Care Suite with FDA-cleared Pneumothorax detection algorithm
NanoVibronix initiates clinical study for UroShield at University of Michigan
Acrivon Therapeutics secures FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Orexo's opioid overdose rescue medication, OX124, gains FDA acceptance for review
SpringWorks Therapeutics' Ogsiveo tablets receive US FDA approval
RedHill Biopharma granted five years' market exclusivity for Talicia by US FDA
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis
Genelux secures FDA Fast Track designation for Olvi-Vec in ovarian cancer
EMA accepts Valneva's chikungunya vaccine application for accelerated assessment
Dupixent shows significant COPD exacerbation reduction in Phase 3 trial, accelerating FDA submission
Everest Medicines Nefecon receives Chinese regulatory approval